Delivery of antisense oligonucleotide using polyethylenimine-based lipid nanoparticle modified with cell penetrating peptide

Shuang Yang, Dandan Wang, Yaojun Sun, Bin ZhengDrug 2019 · DOI

TL;DR

This paper presents a novel lipid nanoparticle (Lp-PPRP) system designed for the efficient delivery of antisense oligonucleotides (ASOs) like LOR-2501. By combining a modified polyethylenimine (PEI-PC) with a cell-penetrating peptide (R8-PA), the Lp-PPRP system demonstrates reduced toxicity and enhanced cellular uptake and gene silencing capabilities compared to traditional PEI-based delivery, suggesting its potential for cancer therapy.

What Problem Does This Paper Address?

Antisense oligonucleotides (ASOs) hold great promise for treating diseases, particularly cancer, by selectively inhibiting gene transcription and translation. However, their clinical application is hampered by challenges related to stability, cellular uptake, and potential toxicity. Polyethylenimine (PEI), a common cationic polymer used for nucleic acid delivery, suffers from high cytotoxicity and limited transfection efficiency. While modifications to PEI and the use of cell-penetrating peptides (CPPs) like octa-arginine (R8) have shown some success, there's a need for a delivery system that synergistically combines the benefits of these approaches to achieve efficient and safe ASO delivery. This paper aims to address this by developing a novel lipid nanoparticle system incorporating both a modified PEI and a modified CPP.

Methods

The researchers synthesized two key components:

  • PEI-PC: Polyethylenimine (PEI) modified with palmitic acid to enhance its hydrophobic properties.
  • R8-PA: Octa-arginine (R8), a known cell-penetrating peptide, modified with palmitic acid to increase its lipophilicity.

These components were then used to construct lipid nanoparticles (Lp-PPRP) encapsulating the ASO LOR-2501. The preparation involved an ethanol dilution method followed by ultrafiltration. The characteristics of these nanoparticles were evaluated using:

  • Dynamic Light Scattering (DLS) and Zeta Potential measurements: To determine particle size, size distribution, and surface charge.
  • Field Emission Scanning Electron Microscopy (FE-SEM): To visualize the morphology of the nanoparticles.
  • Agarose Gel Electrophoresis Retardation Assay: To confirm the successful binding and encapsulation of the ASO within the nanoparticles.
  • MTT Assay: To assess the cytotoxicity of the developed nanoparticles and their components on HeLa and A549 cancer cell lines.
  • Flow Cytometry: To quantify the cellular uptake of Cy3-labeled ASO delivered by different nanoparticle formulations.
  • Western Blot Analysis: To measure the downregulation of the target protein R1, indicating the efficacy of ASO delivery and gene silencing.
  • Confocal Laser Microscopy: To visualize the intracellular localization of the delivered ASO.

Datasets

Not discussed in the paper. The study utilizes established cancer cell lines (HeLa and A549) for in vitro experiments.

Key Insights and Ideas

  • Synergistic Effect of Hydrophobic Modification: Modifying both PEI (PEI-PC) and the CPP (R8-PA) with palmitic acid appears to be crucial. This dual hydrophobic modification likely enhances nanoparticle stability, improves interaction with cell membranes, and facilitates endosomal escape.
  • R8-PA as a Potent Enhancer: The inclusion of R8-PA significantly boosted cellular uptake and transfection efficiency compared to PEI-PC alone. This highlights the power of CPPs, especially when their lipophilicity is optimized.
  • Reduced Cytotoxicity: A major advantage of the Lp-PPRP system is its significantly lower cytotoxicity compared to unmodified PEI, making it a safer delivery vehicle.
  • Targeted Gene Silencing: The Lp-PPRP system effectively delivered the ASO LOR-2501 and achieved substantial downregulation of the R1 protein in both HeLa and A549 cancer cells, demonstrating its functional efficacy.
  • Cytoplasmic Delivery: Confocal microscopy confirmed that the Lp-PPRP system successfully delivered the ASO into the cytoplasm of cancer cells, which is essential for its therapeutic action.

Key Results

  • Nanoparticle Characteristics: The optimized Lp-PPRP/LOR nanoparticles had a suitable particle size of 276.87 ± 5.63 nm and a positive zeta potential of 18.03 ± 0.25 mV, facilitating ASO binding and cellular interaction.
  • Cytotoxicity: While PEI showed significant toxicity, Lp-PP (PEI-PC based) and Lp-PPRP (PEI-PC and R8-PA based) exhibited very low cytotoxicity in both HeLa and A549 cells, with cell viabilities remaining above 90% at tested concentrations.
  • Cellular Uptake: Flow cytometry showed that Lp-PPRP/LOR significantly increased cellular uptake of LOR-2501 compared to Lp-PEI/LOR and Lp-PP/LOR. The mean fluorescence intensity was over three times higher than Lp-PEI/LOR and 1.5 times higher than Lp-PP/LOR.
  • Gene Silencing Efficacy: Lp-PPRP/LOR achieved R1 protein downregulation of 64.56% in HeLa cells and 66.34% in A549 cells, significantly outperforming Lp-PEI/LOR and Lp-PP/LOR.

Limitations and Future Work

  • In Vitro Focus: The study is limited to in vitro experiments. The authors suggest that Lp-PPRP is suitable and effective for further in vivo study for ASO delivery.
  • Optimization Parameters: While optimal ratios for N/P and R8-PA/total lipid were determined, further exploration of other formulation parameters might yield even better results.
  • Specific Cancer Target: The study focused on delivering an ASO targeting R1 for general tumor therapy. Future work could explore tailoring this system for specific cancer types or other therapeutic oligonucleotides.
  • Mechanism of Release: While cytoplasmic delivery was shown, a more detailed investigation into the precise mechanism of ASO release from the nanoparticle within the cell could be beneficial.

Summary updated

Abstract

Efficient and stable delivery system of antisense oligonucleotide (ASO) is important and urgently needed. Here, an ASO delivery system, Lp-PPRP, which contains a cationic polymer based on PEI (branched, 25 kDa), named PEI-PC and a palmitic acid modified R8 (R8-PA) was prepared to deliver a kind of ASO, LOR-2501. The characteristics of the nanoparticles and the cellular uptake of LOR-2501 in HeLa cells and A549 cells were studied. Lp-PPRP showed suitable particle size and zeta potential to combine with LOR-2501; the particle size and zeta potential of Lp-PPRP/LOR were 276.87 ± 5.63 nm and 18.03 ± 0.25 mV. <i>In vitro</i> experiments suggested that Lp-PPRP had lower cytotoxic and higher transfection efficiency for delivering LOR-2501 compared with PEI. The addition of PEI-PC and R8-PA contributed to enhance the transfection efficiency of the nanoparticles. In HeLa cells and A549 cells, Lp-PPRP could transport LOR-2501 and down-regulate the level of R1 protein efficiently, and the R1 down regulations were 64.56% and 66.34%, respectively. Results suggested potential utility of Lp-PPRP in the development of ASO in tumor therapy.
BibTeX
@inproceedings{yang2019delivery,
  author = {Shuang Yang and Dandan Wang and Yaojun Sun and Bin Zheng},
  title = {{Delivery of antisense oligonucleotide using polyethylenimine-based lipid nanoparticle modified with cell penetrating peptide}},
  booktitle = {Drug},
  year = {2019},
  doi = {10.1080/10717544.2019.1667453},
}
Figure